Melatonin is a potential inhibitor of ovarian cancer: molecular aspects
Abstract Ovarian cancer is one of the most common causes of morbidity related to gynecologic malignancies. Possible risk factors are including hereditary ovarian cancer, obesity, diabetes mellitus, alcohol consumption, aging, and smoking. Various molecular signaling pathways including inflammation,...
Main Authors: | Hadis Zare, Rana Shafabakhsh, Russel J. Reiter, Zatollah Asemi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-03-01
|
Series: | Journal of Ovarian Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13048-019-0502-8 |
Similar Items
-
Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression
by: Zhongyu Wang, et al.
Published: (2021-07-01) -
Resveratrol is a promising agent for colorectal cancer prevention and treatment: focus on molecular mechanisms
by: Mohadese Honari, et al.
Published: (2019-07-01) -
Metastatic renal cell carcinoma management
by: Flavio L. Heldwein, et al.
Published: (2009-06-01) -
Melatonin: an anti-tumor agent for osteosarcoma
by: Hadis Fathizadeh, et al.
Published: (2019-11-01) -
Quercetin: a natural compound for ovarian cancer treatment
by: Rana Shafabakhsh, et al.
Published: (2019-06-01)